David Meerkin - 2nd Global LAAO Summit: Highlights of clinical trials in LAA Occlusion therapy & Cardiology referral patients
About this lecture
Discuss trials available, focus on the highlights and new data presented at EuroPCR 2012 - incl. Amplatzer Cardiac Plug EU Post Marketing study and Dr Meerkin's own data. Cardiology referral patients: Patient conditions, history and potential reasons for LAA closure therapy. Lessons to be learned form the specialists working in this area; how to address their needs and how to get to them-ensuring a network and pathway will be developed for eligible Left Atrial Appendage occlusion patients.
- 2nd Global LAAO Summit
David Hildick Smith - What’s new: clinical data published and presented since last year
New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Matthew Price - What’s new: cost effectiveness and health economics
Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
John Camm, Hans Christop Diener - Debate: Are the new ESC guidelines too strict for LAA Occlusion?
John Camm, UK vs Hans Christoph Diener, DEU Debate: Are the new ESC guidelines are too strict for Left Atrial Appendage Occlusion? John Camm - Yes, they are too strict. There is a larger group that should benefit from LAA occlusion and it should be stronger recommended too!Hans Christoph Diener - No, the ESC guidelines are right; LAA occlusion Should be limited to OAC contraindicated patients!